

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington, D.C. 20231, on  
July 12, 2002

Atty Docket No.: 407T-893910US  
Client Ref: UC 99-279-2

By: Quinn Intellectual Property Law Group, P.C.

By: Chianti Apping

JUL 19 2002

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

**PAUL A. PRICE**

Examiner: unassigned

Application No.: **10/045,596**

Art Unit: unassigned

Filed: **10/18/2001**

For: **A FETUIN-MGP-MINERAL  
COMPLEX IN SERUM**

**PRELIMINARY AMENDMENT TO  
ACCOMPANY NOTICE OF MISSING  
PARTS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This preliminary amendment accompanies the Notice to File Missing Parts of Nonprovisional Application mailed on April 24, 2002, containing instructions to comply with the requirements of 37 C.F.R. §§1.821-1.825. The following documents are enclosed herewith:

- 1) A petition to extend the period of response for one month;
- 2) An initial Computer readable form (CRF) copy of the Sequence Listing; and
- 3) An initial paper copy of the Sequence Listing.

Please amend the claims and/or specification as follows

**IN THE SPECIFICATION.**

After the abstract, please insert the accompanying sequence listing (page1).

Delete paragraph 176 on page 62 and insert the following:

--[0001] We next examined the possible sedimentation of the serum calcium phosphate complex during centrifugation, a property that might be anticipated for the complex based on the fact that calcium phosphate mineral phases typically have densities about 3 fold greater than serum. As shown in Table II, centrifugation of serum from rats treated with the 32mg dose of etidronate resulted in a pellet containing calcium, phosphate, and MGP. When the pellet was dissolved in acid